CTIS2023-508637-14-00进行中(未招募)1 期
Multicentric trial on the use of combined therapy of Thiamine and biotine in patients with Huntington´s disease. - HUNTIAM
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla0 个研究点目标入组 24 人开始时间: 2024年5月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Adult patients with Huntington's disease manifested by motor symptoms (chorea, dystonia or bradykinesia) and/or neuropsychiatric symptoms; and genetic confirmation of a number of repetitions of the CAG triplet in the HTT gene (coding for HTT) greater than or equal to 39 repetitions., Women of childbearing age must have a negative serum or urine pregnancy test result at the screening visit. Likewise, they must accept the use of adequate contraceptive methods at least 15 days prior to the screening visit, during the course of the clinical trial and at least 15 days after the last visit., In men who have a partner of childbearing age, accept the use of contraceptive methods., Ability to give informed consent and comply with the visits stipulated in the study.
排除标准
- •Clinically significant medical problems that, in the judgment of the investigators, may cause tissue damage to the CNS or limit its repair, or that may expose the patient to unjustified risk or harm, or cause the patient not to complete the study., Pregnancy or breastfeeding, or planning to become pregnant or patients of childbearing age not undergoing birth control methods (recommended by the Clinical Trial Facilitation Group (CTFG): http://www.hma.eu/fileadmin/dateien/Human_Medicines/ 01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)., Patients dependent on basic activities of daily living (ABDL) or with a degree of severe cognitive impairment that prevents participation/follow-up in the study (UHDRS, Unified Huntington Disease Rating Scale TFC < 7)., Patients with active psychosis at the time of clinical evaluation., Advanced kidney failure.
研究者
相似试验
已完成
不适用
The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcerGastric ulcerJPRN-UMIN000008161Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine40
招募中
不适用
The study for the efficacy of the combine therapy with proton pump inhibitor and rebamipide for the post-endoscopic submucosal dissection (ESD) gastric ulcergastric ulcerJPRN-UMIN000007435Kyushu University140
尚未招募
不适用
Exploratory Clinical Study on Combination Therapy with Anamorelin and Component Nutrients for Cancer Cachexia Complicated by Pancreatic Cancerpancreatic carcinomaJPRN-UMIN000047788Osaka Medical and Pharmaceutical University100
尚未招募
不适用
The study about the effect of combination therapy of active form of vitamin D and lanthanum carbonate for serum concentration of FGF23chronic kidney diseaseJPRN-UMIN000030503Fujita Health University100
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
